LNP023 Clinical Trials
4 recruitingDrug
Phase 33
Showing 1–4 of 4 trials
Recruiting
Phase 3
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Novartis Pharmaceuticals12 enrolled13 locationsNCT06934967
Recruiting
Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals225 enrolled50 locationsNCT03955445
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
Novartis Pharmaceuticals80 enrolled9 locationsNCT06931691